We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
+32.12%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$34.3M
AUM Growth
+$5.46M
Cap. Flow
+$719K
Cap. Flow %
2.1%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$719K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.32%
2 Miscellaneous 2.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.67B
$17.4M 50.6%
982,270
– –
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10.3M 30.07%
662,063
– –
TARA icon
3
Protara Therapeutics
TARA
$236M
$3.34M 9.72%
41,698
+12,564
+43% +$719K
ARGS
4
DELISTED
Argos Therapeutics, Inc.
ARGS
$2.38M 6.93%
662,114
– –
ARGS
5
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$919K 2.68%
256,030
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q3 2017 Portfolio in Review

As of Q3 2017, Pharmstandard International held 5 positions worth $34.3M, up 19% from $28.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 0%. Pharmstandard International opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

  • Pharmstandard International added most to Protara Therapeutics in Q3 2017, an estimated $719K increase.
  • Pharmstandard International's ten largest holdings make up 100% of its $34.3M portfolio in Q3 2017.
  • Pharmstandard International opened 0 new positions and closed 0 in Q3 2017.
  • Pharmstandard International's portfolio value rose 19% quarter-over-quarter to $34.3M.

Based on Pharmstandard International's 13F filing for Q3 2017, filed 3 Nov 2017.